cyclosporine has been researched along with Arterial Occlusive Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isshiki, A; Matsumoto, S; Watanabe, Y; Wieloch, T | 1 |
| Burke, E; Burkhoff, D; Edwards, N; Itescu, S; LaManca, J; Mancini, D; Marks, AR; Oz, M; Pinney, S | 1 |
| Fujishiro, J; Hakamata, Y; Hashizume, K; Kobayashi, E; Kudou, S; Murakami, T; Suzuki, C; Takahashi, M; Yasue, T | 1 |
| Gidding, JC; Ishii, H; Kaneko, T; Muraki, T; Sasaki, Y; Yamamoto, J | 1 |
| Janelidze, S; Kuroda, S; Siesjö, BK | 1 |
| Altavilla, D; Arlotta, M; Bova, A; Campo, GM; Caputi, AP; Deodato, B; Ferlito, M; Minutoli, L; Quartarone, C; Saitta, A; Sardella, A; Squadrito, F; Squadrito, G; Urna, G | 1 |
1 trial(s) available for cyclosporine and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Use of rapamycin slows progression of cardiac transplantation vasculopathy.
Topics: Arterial Occlusive Diseases; Autoantibodies; Cardiac Catheterization; Cohort Studies; Coronary Artery Disease; Cyclosporine; Disease Progression; Female; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Prospective Studies; Renal Insufficiency; Sirolimus; Survival Analysis; Treatment Outcome | 2003 |
5 other study(ies) available for cyclosporine and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion.
Topics: Animals; Arterial Occlusive Diseases; Blood-Brain Barrier; Brain; Coloring Agents; Cyclosporine; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Ischemic Attack, Transient; Male; Middle Cerebral Artery; Neuroprotective Agents; Rats; Rats, Wistar; Tetrazolium Salts | 2002 |
Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats.
Topics: Animals; Aorta; Aortic Diseases; Arterial Occlusive Diseases; Blood Cell Count; Cyclosporine; Drug Therapy, Combination; Hyperplasia; Immunohistochemistry; Immunosuppressive Agents; Kidney Diseases; Macrophages; Male; Mycophenolic Acid; Rats; Rats, Inbred Strains; Receptors, Lysosphingolipid; Retreatment; Sulfhydryl Compounds; T-Lymphocytes; Transplantation, Homologous; Tunica Intima | 2006 |
Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo.
Topics: Animals; Arterial Occlusive Diseases; Cyclosporine; Disease Models, Animal; Male; Platelet Aggregation; Rats; Rats, Wistar; Tacrolimus; Thrombin; Thrombosis | 1995 |
The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats.
Topics: Analysis of Variance; Animals; Arterial Occlusive Diseases; Cerebral Infarction; Cyclosporine; Hyperglycemia; Immunosuppressive Agents; Ischemic Attack, Transient; Male; Neuroprotective Agents; Rats; Rats, Wistar; Tacrolimus; Treatment Outcome | 1999 |
Protective effects of cyclosporin-A in splanchnic artery occlusion shock.
Topics: Animals; Aorta; Arterial Occlusive Diseases; Blood Pressure; Cyclosporine; Enzyme Activation; Immunosuppressive Agents; Male; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Rats; Rats, Sprague-Dawley; Shock; Splanchnic Circulation; Tumor Necrosis Factor-alpha | 2000 |